In a filing, Denali Therapeutics Inc revealed its Director SATO VICKI L unloaded Company’s shares for reported $30471.0 on Apr 15 ’24. In the deal valued at $18.29 per share,1,666 shares were sold. As a result of this transaction, SATO VICKI L now holds 118,043 shares worth roughly $1.84 million.
Then, Krognes Steve E. sold 92,500 shares, generating $1,896,250 in total proceeds. Upon selling the shares at $20.50, the Director now owns 47,341 shares.
Before that, SATO VICKI L sold 1,666 shares. Denali Therapeutics Inc shares valued at $33,487 were divested by the Director at a price of $20.10 per share. As a result of the transaction, SATO VICKI L now holds 119,709 shares, worth roughly $1.87 million.
Citigroup initiated its Denali Therapeutics Inc [DNLI] rating to a Buy in a research note published on December 13, 2023; the price target was $32. B. Riley Securities started covering the stock on September 06, 2023. It rated DNLI as “a Buy”.
Price Performance Review of DNLI
On Monday, Denali Therapeutics Inc [NASDAQ:DNLI] saw its stock jump 1.10% to $15.60. Over the last five days, the stock has lost -2.44%. Denali Therapeutics Inc shares have fallen nearly -27.31% since the year began. Nevertheless, the stocks have fallen -35.46% over the past one year. While a 52-week high of $33.31 was reached on 02/27/24, a 52-week low of $14.56 was recorded on 04/25/24. SMA at 50 days reached $18.90, while 200 days put it at $20.64. A total of 0.91 million shares were traded, compared to the trading of 0.94 million shares in the previous session.
Levels Of Support And Resistance For DNLI Stock
The 24-hour chart illustrates a support level at 15.34, which if violated will result in even more drops to 15.08. On the upside, there is a resistance level at 15.91. A further resistance level may holdings at 16.22. The Relative Strength Index (RSI) on the 14-day chart is 33.95, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.39, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 77.63%. Stochastics %K at 15.61% indicates the stock is a buying.
The most recent change occurred on January 30, 2023 when SVB Securities began covering the stock and recommended ‘”an Outperform”‘ rating along with a $50 price target.
